Endometrial cancer: ©freshidea - stock.adobe.com Findings from an analysis of the Study 111/KEYNOTE-146 study (NCT02501096) identified that lenvatinib (Lenvima) plus pembrolizumab (Keytruda) was an efficacious combination for patients with previously treated endometrial carcinoma, eliciting responses...